{"id":82275,"date":"2024-07-08T15:37:01","date_gmt":"2024-07-08T15:37:01","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/truvetas-real-world-data-study-comparing-tirzepatide-mounjaro-and-semaglutide-ozempic-for-weight-loss-published-in-jama-internal-medicine\/"},"modified":"2024-07-08T15:37:01","modified_gmt":"2024-07-08T15:37:01","slug":"truvetas-real-world-data-study-comparing-tirzepatide-mounjaro-and-semaglutide-ozempic-for-weight-loss-published-in-jama-internal-medicine","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/truvetas-real-world-data-study-comparing-tirzepatide-mounjaro-and-semaglutide-ozempic-for-weight-loss-published-in-jama-internal-medicine\/","title":{"rendered":"Truveta\u2019s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine"},"content":{"rendered":"
\n

BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) — Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine<\/i><\/a>.<\/p>\n

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA\/gastric inhibitory polypeptide (GIP) medication tirzepatide, are used to treat type 2 diabetes or obesity. In the study published in JAMA Internal Medicine<\/i><\/a>, Truveta Research compared weight loss outcomes for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively). The study can also be viewed directly within Truveta Studio<\/a>.<\/p>\n

In this study, Truveta Research studied patients with overweight or obesity initiating either semaglutide or tirzepatide between May 2022 and September 2023. The team used multiple rigorous methods (including propensity score matching) to achieve a well-balanced analytic cohort of more than 18,000 patients to appropriately evaluate the effectiveness of semaglutide compared with tirzepatide for weight loss. The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss:<\/p>\n